Kv11.1 Channels as Novel Targets for the Treatment of Pulmonary Arterial Hypertension

BACKGROUND

PAH is a rare, progressive condition characterized by elevated pulmonary arterial pressures leading to right ventricular failure. Current treatments only alleviate symptoms without offering a cure. This invention addresses the need for new therapeutic approaches by identifying Kv11.1 channels as potential targets for PAH treatment, offering a novel pathway for drug development and repurposing.

Benefit

• Offers a new approach to treating PAH by targeting Kv11.1 channels
• Potential for repurposing an existing FDA-approved drug, potentially accelerating the path to clinical use
• Provides a deeper understanding of PAH pathophysiology, opening avenues for further research
• May lead to more effective treatments for PAH, improving patient outcomes
• Could reduce the economic burden of PAH treatment by repurposing an existing medication

Market Application

• Potential use in developing new targeted therapies for pulmonary arterial hypertension
• Possible application in treating other forms of pulmonary hypertension, such as COPD-associated PH
• Can be implemented in clinical trials to evaluate dofetilide's efficacy in PAH treatment
• Suitable for pharmaceutical companies focused on respiratory and cardiovascular diseases

Intellectual property status

Granted Patent

Patent number : Patent No. 11,529,324

Where : USA